CTOs on the Move

Areteia Therapeutics

www.areteiatx.com

 
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.areteiatx.com
  • 12770 High Bluff Drive Suite 380
    San Diego, CA USA 92130
  • Phone: 858.987.4278

Executives

Name Title Contact Details

Similar Companies

Capital Royalty L.P.

Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

BioLabs

BioLabs is the premier co-working space for life science startups.

Luzsana Biotechnology

Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.

Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.